Rocket Pharmaceuticals, Inc.: share-based compensation expense
Share-based compensation expense for Rocket Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Rocket Pharmaceuticals, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 37,059,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076551 |
| 2024-01-01 | 2024-12-31 | 43,920,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076551 |
| 2023-01-01 | 2023-12-31 | 39,406,000 | USD | 2025-02-27 | 10-K · 0000950170-25-029002 |
| 2022-01-01 | 2022-12-31 | 31,009,000 | USD | 2025-02-27 | 10-K · 0000950170-25-029002 |
| 2021-01-01 | 2021-12-31 | 29,237,000 | USD | 2024-02-27 | 10-K · 0000950170-24-021096 |
| 2020-01-01 | 2020-12-31 | 18,567,000 | USD | 2023-02-28 | 10-K · 0001140361-23-009252 |
| 2019-01-01 | 2019-12-31 | 13,371,000 | USD | 2022-02-28 | 10-K · 0001140361-22-007036 |
| 2018-01-01 | 2018-12-31 | 13,601,000 | USD | 2021-03-01 | 10-K · 0001140361-21-006677 |
| 2017-01-01 | 2017-12-31 | 1,320,000 | USD | 2019-03-08 | 10-K · 0001140361-19-004603 |
| 2016-01-01 | 2016-12-31 | 274,000 | USD | 2019-03-08 | 10-K · 0001140361-19-004603 |
| 2015-01-01 | 2015-12-31 | 2,380,000 | USD | 2017-03-16 | 10-K · 0001564590-17-004532 |
| 2014-01-01 | 2014-12-31 | 177,000 | USD | 2016-03-23 | 10-K · 0001193125-16-514228 |
Related financial histories
- Rocket Pharmaceuticals, Inc.: total assets
- Rocket Pharmaceuticals, Inc.: total liabilities
- Rocket Pharmaceuticals, Inc.: stockholders equity
- Rocket Pharmaceuticals, Inc.: cash and cash equivalents
- Rocket Pharmaceuticals, Inc.: net income or loss
- Rocket Pharmaceuticals, Inc.: operating cash flow
- Rocket Pharmaceuticals, Inc.: capital expenditure payments
- Rocket Pharmaceuticals, Inc.: contract revenue excluding tax
- Rocket Pharmaceuticals, Inc.: financing cash flow
- Rocket Pharmaceuticals, Inc.: investing cash flow
- Rocket Pharmaceuticals, Inc.: retained earnings or deficit
- Rocket Pharmaceuticals, Inc.: basic weighted-average shares
- Rocket Pharmaceuticals, Inc.: diluted weighted-average shares
- Rocket Pharmaceuticals, Inc.: basic earnings per share
- Rocket Pharmaceuticals, Inc.: diluted earnings per share
- Rocket Pharmaceuticals, Inc.: net property, plant and equipment
- Rocket Pharmaceuticals, Inc.: operating income or loss
- Rocket Pharmaceuticals, Inc.: current assets
- Rocket Pharmaceuticals, Inc.: interest expense
- Rocket Pharmaceuticals, Inc.: current liabilities
- Rocket Pharmaceuticals, Inc.: current accounts payable
- Rocket Pharmaceuticals, Inc.: goodwill carrying amount
- Rocket Pharmaceuticals, Inc.: common-stock repurchase payments
- Rocket Pharmaceuticals, Inc.: operating expenses
- Rocket Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Rocket Pharmaceuticals, Inc. / CIK 0001281895
- Captured
- 2026-09-20T07:48:45.204Z
- SEC response SHA-256
0bcbe84a05b7de7c12edb430923484b522633d995abac19aad70bdfd9e60b3ef
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001281895.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))